The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media.

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware of the current global shortage of iodinated contrast media. The following statement offers some recommendations on how providers may address this emergency locally. The recommendations are not exhaustive or prescriptive. They are intended as a resource for imaging providers and their institutions to continue to provide high-quality patient care during times of shortage of contrast media. Providers and administrative leaders are encouraged to incorporate sound clinical judgment in all decisions affecting patient care.

The ACR recognizes that this is a rapidly evolving situation. Guidance may be revised as circumstances continue to change.

The ACR Committee on Drugs and Contrast Media recommends the following considerations for facilities operating during a time of iodinated contrast media shortages.

Risk mitigation strategies during an iodinated contrast shortage include:

  • Utilize alternative studies to answer the clinical question such as non-contrast CT, MR with or without gadolinium-based contrast media, ultrasound with or without ultrasound contrast agents,
    nuclear medicine, or PET/CT, when feasible. Please refer to the ACR Appropriateness Criteria guidelines for indicated alternative studies as needed. (Scroll down to AC Portal and use the “Explore by scenario” icon.)
  • Look for alternative versions of contrast agents, which may be marketed under a different brand name or intended clinical use. (Note: US market availability may differ from global availability.)
  • Source contrast from other vendors, if able, and consider having at least two vendor products on formulary
  • If you currently have access to higher volume single-use vials, contact your institutional pharmacy to determine if it is possible to repackage vials in smaller aliquots to reduce waste (institution level).
  • Minimize individual doses administered to reduce waste. Some options include:
    • Weight-based dosing for CT in available aliquots/vial sizes to avoid waste
    • Reducing dose in conjunction with low kVp protocols that improve contrast conspicuity
    • Reducing dose and acquire studies with dual-energy protocols (where available) that improve contrast conspicuity
  • Reserve higher concentration (mg iodine / ml) agents for angiographic studies and multiphase studies, which require optimal vascular visualization.
  • Use alternatives to nonionic contrast for oral, rectal, genitourinary administration (examples: iothalamate meglumine or diatrizoate). Consider barium-based products for oral opacification in CT and PET/CT, as well as alternative iodine-based agents (ionics). (Please refer to the ACR Contrast Manual APPENDIX A: Contrast Media Specifications Table for oral contrast agents).
  • Work with other departments, such as Urology, Radiation Oncology, Pain Management, Gastroenterology, Vascular Surgery and Cardiology, which utilize iodinated contrast to prioritize limited supply usage.

Considerations

  • Do not sacrifice image quality by using suboptimal doses; ensure enough contrast dose is used for diagnostic image quality.
  • CDC and Joint Commission guidelines state that vials labeled by the manufacturer as “single dose” or “single use” should only be used for a single patient because they typically lack antimicrobial preservatives and can become contaminated and serve as a source of infection when used improperly. Several instances of iatrogenic infection have been reported with improper use of single use vials for multiple patients with basic infection control techniques often violated.  Some of these events occurred during times of medication shortages as an effort to reduce waste.  However, the CDC issued a statement in May of 2012  that offered guidance for how contents from unopened singe-dose/single-use vials can be repackaged for multiple patients but only performed by qualified healthcare personnel in accordance with standards in United States Pharmacopeia General Chapter <797> Pharmaceutical Compounding-Sterile Preparation. The ASHP, an organization representing pharmacists, posted their guidance  as well.
    •  In the setting of severe shortage, institutions can explore developing their own guidelines for the safe use of single-use vials for more than one patient following proper infection control guidance and ensuring institution approval since this would deviate from medication and regulatory guidelines.

For more information: www.acr.org

Related Content of MRI Gadolinium Safety Concerns

Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

Related Content

News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 10, 2022 — At the ISMRM 2022 conference, Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction ...

Time May 10, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 9, 2022 — At the International Society for Magnetic Resonance in Medicine (ISMRM) 2022 Annual Meeting, GE Healthcare ...

Time May 09, 2022
arrow
News | Nuclear Imaging

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 9, 2022 — For some sports such as tennis, the wrist is frequently under stress, and an injury to the wrist can ...

Time May 09, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 9, 2022 — Royal Philips, a global leader in health technology, announced it has received FDA 510(k) clearance for ...

Time May 09, 2022
arrow
News | Proton Therapy

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
Subscribe Now